Management of brain metastases in non–small-cell lung cancer

Vinicius Ernani, Thomas E. Stinchcombe

Research output: Contribution to journalReview article

Abstract

Lung cancer is the leading cause of cancer-related death in the United States. Approximately 20% of these patients present with brain metastases (BMs). Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy have historically been the primary treatment modalities for patients with non–small-cell lung cancer (NSCLC) and BMs. The treatments for BMs have become complex with the discovery of targetable molecular drivers and the development of an astonishing number of tyrosine kinase inhibitors. Many of these tyrosine kinase inhibitors have robust and durable efficacy against CNS metastases. In many circumstances, these drugs can defer local therapy and even reduce the risk of CNS progression. More recently, immune checkpoint inhibitors have changed the treatment landscape for many patients with NSCLC; however, the role of immunotherapy in patients with BMs is the subject of ongoing investigations. This article will review the current data and our approach to patients with NSCLC and BMs.

Original languageEnglish (US)
Pages (from-to)563-570
Number of pages8
JournalJournal of oncology practice
Volume15
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Brain Neoplasms
Protein-Tyrosine Kinases
Radiosurgery
Therapeutics
Immunotherapy
Lung Neoplasms
Radiotherapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Management of brain metastases in non–small-cell lung cancer. / Ernani, Vinicius; Stinchcombe, Thomas E.

In: Journal of oncology practice, Vol. 15, No. 11, 01.01.2019, p. 563-570.

Research output: Contribution to journalReview article

Ernani, Vinicius ; Stinchcombe, Thomas E. / Management of brain metastases in non–small-cell lung cancer. In: Journal of oncology practice. 2019 ; Vol. 15, No. 11. pp. 563-570.
@article{3845aebeefc94aac9c7f613d31865d39,
title = "Management of brain metastases in non–small-cell lung cancer",
abstract = "Lung cancer is the leading cause of cancer-related death in the United States. Approximately 20{\%} of these patients present with brain metastases (BMs). Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy have historically been the primary treatment modalities for patients with non–small-cell lung cancer (NSCLC) and BMs. The treatments for BMs have become complex with the discovery of targetable molecular drivers and the development of an astonishing number of tyrosine kinase inhibitors. Many of these tyrosine kinase inhibitors have robust and durable efficacy against CNS metastases. In many circumstances, these drugs can defer local therapy and even reduce the risk of CNS progression. More recently, immune checkpoint inhibitors have changed the treatment landscape for many patients with NSCLC; however, the role of immunotherapy in patients with BMs is the subject of ongoing investigations. This article will review the current data and our approach to patients with NSCLC and BMs.",
author = "Vinicius Ernani and Stinchcombe, {Thomas E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1200/JOP.19.00619",
language = "English (US)",
volume = "15",
pages = "563--570",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Management of brain metastases in non–small-cell lung cancer

AU - Ernani, Vinicius

AU - Stinchcombe, Thomas E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lung cancer is the leading cause of cancer-related death in the United States. Approximately 20% of these patients present with brain metastases (BMs). Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy have historically been the primary treatment modalities for patients with non–small-cell lung cancer (NSCLC) and BMs. The treatments for BMs have become complex with the discovery of targetable molecular drivers and the development of an astonishing number of tyrosine kinase inhibitors. Many of these tyrosine kinase inhibitors have robust and durable efficacy against CNS metastases. In many circumstances, these drugs can defer local therapy and even reduce the risk of CNS progression. More recently, immune checkpoint inhibitors have changed the treatment landscape for many patients with NSCLC; however, the role of immunotherapy in patients with BMs is the subject of ongoing investigations. This article will review the current data and our approach to patients with NSCLC and BMs.

AB - Lung cancer is the leading cause of cancer-related death in the United States. Approximately 20% of these patients present with brain metastases (BMs). Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy have historically been the primary treatment modalities for patients with non–small-cell lung cancer (NSCLC) and BMs. The treatments for BMs have become complex with the discovery of targetable molecular drivers and the development of an astonishing number of tyrosine kinase inhibitors. Many of these tyrosine kinase inhibitors have robust and durable efficacy against CNS metastases. In many circumstances, these drugs can defer local therapy and even reduce the risk of CNS progression. More recently, immune checkpoint inhibitors have changed the treatment landscape for many patients with NSCLC; however, the role of immunotherapy in patients with BMs is the subject of ongoing investigations. This article will review the current data and our approach to patients with NSCLC and BMs.

UR - http://www.scopus.com/inward/record.url?scp=85074958695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074958695&partnerID=8YFLogxK

U2 - 10.1200/JOP.19.00619

DO - 10.1200/JOP.19.00619

M3 - Review article

C2 - 31715122

AN - SCOPUS:85074958695

VL - 15

SP - 563

EP - 570

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 11

ER -